CoChat

Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis

Open access
Stifano, Giuseppina, Sornasse, Thierry, Rice, Lisa M., Na, Leo, Chen‐Harris, Haiyin, Khanna, Dinesh, Jahreis, Angelika, Zhang, Yuqing, Siegel, Jeff, Lafyatis, Robert · 2018 · Arthritis & Rheumatology
Cited by 62

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Objective: At present, there are no clinical or laboratory measures that accurately forecast the progression of skin fibrosis and organ involvement in patients with systemic sclerosis (SS c). The goal of this study was to identify skin biomarkers that could be prognostic for the progression of skin fibrosis in patients with early diffuse cutaneous SS c (dc SS c). Methods: We analyzed clinical data and gene expression in skin biopsy samples from 38 placebo‐treated patients, part of the Roche Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis (FASSCINATE) phase II study of tocilizumab in SS c. RNA samples were analyzed using nC ounter. A trajectory model based on a modified Rodnan skin thickness score was used to describe 3 skin disease trajectories over time. We examined the association of skin gene expression with skin score trajectory groups, by chi‐square test. Logistic regression was used to examine the prognostic power of each gene identified. Results: We found that placebo‐treated patients with high expression of messenger RNA for CD 14, SERPINE 1, IL 13 RA 1, CTGF, and OSMR at baseline were more likely to have progressive skin score trajectories. We also found that those genes were prognostic for the risk of skin progression and that IL 13 RA 1, OSMR, and SERPINE 1 performed the best. Conclusion: Skin gene expression of biomarkers associated with macrophages (CD 14, IL 13 RA 1) and transforming growth factor β activation (SERPINE 1, CTGF, OSMR) are prognostic for progressive skin disease in patients with dc SS c. These biomarkers may provide guidance in decision‐making about which patients should be considered for aggressive therapies and/or for clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.40455

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

Metadata

Authors
Stifano, G., Sornasse, T., Rice, L. M., Na, L., Chen‐Harris, H., Khanna, D., Jahreis, A., Zhang, Y., Siegel, J., & Lafyatis, R.
Venue
Arthritis & Rheumatology
Publisher
Wiley
Published
2018-05-28
Volume
70
Issue
6
Pages
912-919
ISSN
  • 2326-5191 (ISSN-L)
  • 2326-5205
OpenAlex
W2807240358
Cited by
62
References
3
FWCI
3.86
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.